Caris Life Sciences, Inc. Common Stock (CAI) Stock
Key stats
- Market cap
- $7.02B
- Price / Earnings ratio
- 72.9x
- EPS (TTM)
- $1.66
- Volume
- Loading
- 52-week high
- $36.50
- 52-week low
- $14.19
Source: third-party data provider, as of November 13, 2026
Compare with CAI
Recent news

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
CAI

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
CAI

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
CAI

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2
Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2
CAI
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 33.88
- MACD 12/26/9
- -1.07
- EMA 9 of MACD
- 0.13
- MACD histogram
- -1.21
- SMA 50
- $29.45
- Price below SMA 50
- EMA 50
- $28.61
- Price below EMA 50
- SMA 200
- $21.65
- Price above SMA 200
- EMA 200
- $24.37
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
CAI

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
CAI

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
CAI

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2
Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2
CAI

Caris Life Sciences Q2 Earnings Call Highlights
Caris Life Sciences Q2 Earnings Call Highlights
CAI

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
CAI

BTSG vs. CAI: Which Stock Is the Better Value Option?
BTSG vs. CAI: Which Stock Is the Better Value Option?
CAI

Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect?
Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect?
CAI

June IPOs to Watch Closely
June IPOs to Watch Closely
CAI
News tone: automated (AI) classification of the article's content, not a price prediction.
About Caris Life Sciences, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David Dean Halbert M.D. | Chairman, CEO & Founder | 1956 |
| Mr. Luke Power | Senior VP, CFO & Chief Accounting Officer | 1982 |
| Mr. Brian J. Brille J.D. | Executive Vice Chairman & Executive VP | 1961 |
| Dr. David Spetzler M.B.A., M.S., Ph.D. | President | 1977 |
| Mr. J. Russel Denton | Senior VP, General Counsel & Secretary | 1984 |
| Mr. Jon Mark Harmon | Senior VP & Chief Operations Officer | — |
| Dr. Valeriy Domenyuk | Senior VP & CTO | — |
| Dr. Milan Radovich Ph.D. | Senior VP & Chief Scientific Officer | — |
| Mr. Jeremy O'Brien | Senior Vice President of Human Resources & Chief Compliance Officer | — |
| Mr. Narendra Chokshi | Senior Vice President of Corporate Development | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.88
- MACD 12/26/9
- -1.07
- EMA 9 of MACD
- 0.13
- MACD histogram
- -1.21
- SMA 50
- $29.45
- Price below SMA 50
- EMA 50
- $28.61
- Price below EMA 50
- SMA 200
- $21.65
- Price above SMA 200
- EMA 200
- $24.37
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $25.00
- Average
- $32.86
- High
- $38.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.1 | |||||||||||
| 2025 | -4.6 | +5.9 | +36.9 | -17.3 | -0.8 | -14.7 | +3.6 | |||||
| 2026 | -14.2 | -13.6 | -13.5 | -0.7 | -9.5 | +8.3 | -16.4 | +56.2 | +23.6 | +21.1 | -23.7 |



